Cat. No. 2615
Chemical Name: N4-(3-Bromophenyl)-N6-methyl-pyrido
Biological ActivityPotent inhibitor of ErbB receptor family tyrosine kinases (IC50 values are 0.008, 49 and 52 nM for EGFR, ErbB2 and ErbB2/ErbB4 respectively) that does not inhibit FGF or PDGF-mediated tyrosine phosphorylation. Induces G1 cell cycle arrest in MCF10A cells and is antiproliferative in A431 human epidermal carcinoma cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Gonzales et al (2005) G1 cell cycle arrest due to inhibition of erbB family receptor tyrosine kinases does not require the retinoblastoma protein. Exp.Cell Res. 303 56. PMID: 15572027.
Sun et al (1999) Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors. Anticancer Res. 19 919. PMID: 10368634.
Fry et al (1997) Biochemical and antiproliferative properties of 4-[ar(alk)ylmino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochem.Pharmacol. 54 877. PMID: 9354588.
If you know of a relevant reference for PD 158780 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses PD 158780 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: PD 158780, supplier, Potent, ErbB, receptor, family, inhibitors, inhibits, Epidermal, Growth, Factors, Receptors, Her, EGFR, Receptor, Tyrosine, Kinases, RTKs, PD158780, Tocris Bioscience, EGFR Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective PDGFR inhibitorGSK 1363089
Potent inhibitor of MET, VEGFR2, Ron and AXL
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.